| Dr Archana Bhargava, MD | |
|
789 Central Ave, Dover, NH 03820-2526 | |
| (603) 742-8787 | |
| Not Available |
| Full Name | Dr Archana Bhargava |
|---|---|
| Gender | Female |
| Speciality | Hematology/oncology |
| Experience | 27 Years |
| Location | 789 Central Ave, Dover, New Hampshire |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366457004 | NPI | - | NPPES |
| 3098108 | Medicaid | NH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 12289 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wentworth-douglass Hospital | Dover, NH | Hospital |
| Frisbie Memorial Hospital | Rochester, NH | Hospital |
| Huggins Hospital | Wolfeboro, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wentworth Douglass Physician Corporation | 5496749848 | 372 |
News Archive
Research suggests that there is no long-term advantage, in terms of cardioprotection or event-free survival, from giving continuous instead of bolus doxorubicin infusion in children with acute lymphoblastic leukemia.
Research led by the Vall d'Hebron Institute of Oncology (VHIO) evidence the most conclusive preclinical results to-date validating Myc inhibition as a therapeutic strategy in glioma - a highly agressive tumor type that notoriously outsmarts current anti-cancer therapies.
Quintiles today announced the availability of anatomic pathology services through its central laboratory in Beijing, China, to help biopharmaceutical companies develop more effective cancer treatments. These services complement assay development, digital pathology and core lab offerings available through the facility to help customers comply with China's restrictions on tissue import/export.
A new study has found that cystic fibrosis patients who have a common virus may experience faster disease progression than patients who do not have the virus. Signs of faster cystic fibrosis disease progression included earlier times to lung transplant referral and reaching the final stages of the disease.
› Verified 8 days ago
| Entity Name | Wentworth Douglass Physician Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447352430 PECOS PAC ID: 5496749848 Enrollment ID: O20040409000433 |
News Archive
Research suggests that there is no long-term advantage, in terms of cardioprotection or event-free survival, from giving continuous instead of bolus doxorubicin infusion in children with acute lymphoblastic leukemia.
Research led by the Vall d'Hebron Institute of Oncology (VHIO) evidence the most conclusive preclinical results to-date validating Myc inhibition as a therapeutic strategy in glioma - a highly agressive tumor type that notoriously outsmarts current anti-cancer therapies.
Quintiles today announced the availability of anatomic pathology services through its central laboratory in Beijing, China, to help biopharmaceutical companies develop more effective cancer treatments. These services complement assay development, digital pathology and core lab offerings available through the facility to help customers comply with China's restrictions on tissue import/export.
A new study has found that cystic fibrosis patients who have a common virus may experience faster disease progression than patients who do not have the virus. Signs of faster cystic fibrosis disease progression included earlier times to lung transplant referral and reaching the final stages of the disease.
› Verified 8 days ago
| Entity Name | Frisbie Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942426952 PECOS PAC ID: 7012996275 Enrollment ID: O20040720000566 |
News Archive
Research suggests that there is no long-term advantage, in terms of cardioprotection or event-free survival, from giving continuous instead of bolus doxorubicin infusion in children with acute lymphoblastic leukemia.
Research led by the Vall d'Hebron Institute of Oncology (VHIO) evidence the most conclusive preclinical results to-date validating Myc inhibition as a therapeutic strategy in glioma - a highly agressive tumor type that notoriously outsmarts current anti-cancer therapies.
Quintiles today announced the availability of anatomic pathology services through its central laboratory in Beijing, China, to help biopharmaceutical companies develop more effective cancer treatments. These services complement assay development, digital pathology and core lab offerings available through the facility to help customers comply with China's restrictions on tissue import/export.
A new study has found that cystic fibrosis patients who have a common virus may experience faster disease progression than patients who do not have the virus. Signs of faster cystic fibrosis disease progression included earlier times to lung transplant referral and reaching the final stages of the disease.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Archana Bhargava, MD Po Box 412503, Boston, MA 02241-2503 Ph: (617) 726-3884 | Dr Archana Bhargava, MD 789 Central Ave, Dover, NH 03820-2526 Ph: (603) 742-8787 |
News Archive
Research suggests that there is no long-term advantage, in terms of cardioprotection or event-free survival, from giving continuous instead of bolus doxorubicin infusion in children with acute lymphoblastic leukemia.
Research led by the Vall d'Hebron Institute of Oncology (VHIO) evidence the most conclusive preclinical results to-date validating Myc inhibition as a therapeutic strategy in glioma - a highly agressive tumor type that notoriously outsmarts current anti-cancer therapies.
Quintiles today announced the availability of anatomic pathology services through its central laboratory in Beijing, China, to help biopharmaceutical companies develop more effective cancer treatments. These services complement assay development, digital pathology and core lab offerings available through the facility to help customers comply with China's restrictions on tissue import/export.
A new study has found that cystic fibrosis patients who have a common virus may experience faster disease progression than patients who do not have the virus. Signs of faster cystic fibrosis disease progression included earlier times to lung transplant referral and reaching the final stages of the disease.
› Verified 8 days ago
Dr. Mark Lee Dick, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 10 Members Way Fl 5, Dover, NH 03820 Phone: 603-609-6800 | |
Mrs. Jhansi Lakshmi Maradana, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 10 Members Way Ste 400, Dover, NH 03820 Phone: 603-742-1143 Fax: 603-749-3509 | |
Ravi Teja Pasam, M.D. Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 789 Central Ave, Dover, NH 03820 Phone: 603-740-2503 Fax: 603-740-2497 | |
Paul C Tung, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 10 Members Way, Suite 400, Dover, NH 03820 Phone: 603-742-1143 Fax: 603-749-3509 | |
Amy Claire Bessnow, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 789 Central Ave, Dover, NH 03820 Phone: 603-740-2694 | |
Dylan Thomas, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 10 Members Way Ste 400, Dover, NH 03820 Phone: 603-742-1143 Fax: 603-749-3509 | |
Alison M Sollee, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 10 Members Way Fl 5, Dover, NH 03820 Phone: 603-609-6800 |